ecancermedicalscience最新文献

{"title":"Breast cancer radiotherapy in Sub-Saharan Africa: a comparative study of acute toxicity between conventional and hypofractionated treatment regimens.","authors":"Joseph Daniels, Tony Obeng-Mensah, Kofi Adesi Kyei","doi":"10.3332/ecancer.2024.1810","DOIUrl":"10.3332/ecancer.2024.1810","url":null,"abstract":"<p><p>Hypofractionated radiotherapy for breast cancer has been increasingly adopted globally due to its comparable efficacy and reduced treatment burden. The study compared the incidence and severity of four main acute radiation-induced toxicities between breast cancer patients treated with conventional versus hypofractionated radiotherapy. Stratified purposive sampling was used to recruit participants into two groups: group #1 received conventional radiotherapy (50 Gy in 25 fractions over 5 weeks), whereas group #2 received hypofractionated radiotherapy (40.05 Gy in 15 fractions over 3 weeks). A closed-ended questionnaire administered by the researcher was used for quantitative data collection. The Common Terminology Criteria for Adverse Events tool (version 5) was used for grading acute toxicities. Data were analyzed using the Statistical Package for Social Sciences (version 23). The study involved 53 patients with a mean age of 47.9 years (± 12.4) ranging from 26 to 75 years. The patients had breast cancer ranging from stage IIA (13.2%) to IIIC (9.4%). A considerable majority (62.3%) were treated with conventional fractionation whereas 37.7% were treated with a hypofractionated regimen. Dermatitis was the most prevalent side effect among patients in both groups #1 (67%) and #2 (70%). There were no statistically significant differences in the incidence of dermatitis, pharyngitis, chest wall/ breast pain and fatigue between the two groups. However, the mean incidence of overall acute toxicity was significantly lower in group #2 (2.15 ± 1.14) compared with group #1 (2.42 ± 1.48), with a p-value of 0.001. Comparatively, the conventional 50 Gy dose regimen was associated with more acute radiation-induced toxicity.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1810"},"PeriodicalIF":1.2,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunohistochemistry effect on diagnostic reliability for paediatric cancer at Mwanza region, Tanzania: a laboratory descriptive study.","authors":"Jeffer O Bhuko, Erius Tebuka, Oscar Ottoman, Kristin Schroeder","doi":"10.3332/ecancer.2024.1809","DOIUrl":"10.3332/ecancer.2024.1809","url":null,"abstract":"<p><strong>Introduction: </strong>In nations with poor and intermediate incomes, cancer is one of the main causes of mortality. Immunohistochemistry (IHC) is crucial for an accurate cancer evaluation, prognosis and treatment decision-making. To use IHC, a significant amount of facilities and capacity growth are needed. Because of this, it is crucial to comprehend the potential effects of IHC and identify the most essential reagents required to distinguish between typical diagnoses in our environment.</p><p><strong>Objective: </strong>Employing IHC, this study aims to assess how well paediatric cancer diagnoses in Tanzania can be made and to identify the most widely used biomarkers for diagnostic distinction.</p><p><strong>Methods: </strong>Pathology samples from kids who were given cancer diagnoses in 2018 at the Bugando Medical Centre in Mwanza, Tanzania, were examined using H&E staining. Basic demographic information from the histology form was gathered in addition to the reported histopathology results from Bugando Medical Centre, including patient age, sex and sample collection. Muhimbili National Hospital received tissue from the histology block for the IHC examination. It was determined which reagents/biomarkers were required for diagnostic confirmation by comparing the histopathology data for diagnostic agreement, variations in diagnosis and other factors.</p><p><strong>Results: </strong>The examinations included 105 (105) patients with paediatric cancer. 55.2% of the population, who had a median age of 6 years (IQR 3-9), were female. Burkitt and NHL-DLBCL were the paediatric diagnoses with the greatest pathology. The correlation between H&E and IHC histology was 51.0%. 17.6% (<i>n</i> = 18) of diagnoses had enhanced diagnostic specificity (e.g., NHL to diffuse large B cell lymphoma), and 31.4% of diagnoses were altered as a result of IHC.</p><p><strong>Conclusion: </strong>Considering that the diagnosis of juvenile cancer changes in about 30% of cases, IHC is crucial for accurate diagnosis. IHC retraining is crucial, and developing nations can successfully adopt a modest shared biomarker panel to improve therapy allocation.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1809"},"PeriodicalIF":1.2,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge of breast cancer among patients undergoing breast cancer treatment at a Tertiary Hospital in Ghana.","authors":"Josephine Nsaful, Florence Dedey, Kirstyn E Brownson, Ruth Y Laryea, Nathaniel Coleman, John Tetteh, Mohammed Albezel Sheriff, Joe-Nat Clegg-Lamptey, Benedict N L Calys-Tagoe","doi":"10.3332/ecancer.2024.1808","DOIUrl":"10.3332/ecancer.2024.1808","url":null,"abstract":"<p><p>Breast cancer is the leading cause of cancer in females worldwide. Western Africa has one of the highest mortality rates globally partly due to late presentation, often attributed to deficits in patient knowledge about the disease. A cross-sectional study was conducted at the Korle Bu Teaching Hospital among breast cancer patients. A structured questionnaire was utilised to collect data on patient demographics; sources of information on breast cancer; risk factors; symptoms; and treatment options. A chi-square test assessed the relationship between the participants' levels of knowledge and demographic characteristics. Univariate and multivariate analyses determined which sociodemographic factors predicted knowledge. p values <0.05 were considered statistically significant. This study enrolled 636 participants with a mean age of 52.6 ± 12.1 years. Television (TV) (63.4%) and radio (44.6%) were the main sources of information about breast cancer. Thirty-two percent of participants knew that family history was an associated risk factor for developing breast cancer. Eighty-three percent of the patients were familiar with self-breast examination, but only 42% of them practiced it. While 76% of participants knew that a breast mass could represent breast cancer, only 13%, 12% and 6% of participants identified nipple discharge, breast skin changes and changes in breast size as concerning symptoms of breast cancer, respectively. Only 7% of patients were aware of breast conservation as a treatment option. A higher educational level and higher monthly income were identified as predictors of a better level of knowledge, while age older than 60 years and advanced-stage disease correlated with decreased knowledge about breast cancer. Breast cancer awareness campaigns in Ghana should be expanded to include all Ghanaians, specifically women of lower socioeconomic status and older than 60 years. Educational messages should emphasise symptoms other than breast masses and the feasibility of breast-conserving surgery as a treatment option for early-stage disease.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1808"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current landscape of BRAF-V600E metastatic CRC management in Latin America: an expert Latin American panel's recommendations.","authors":"Anelisa K Coutinho, Yazmin Carolina Blanco Vazquez, Markus Andret Cavalcante Gifoni, Angela Marie Jansen, Juan Manuel O'Connor, Juan Carlos Samamé Pérez-Vargas, Mariana Rico-Restrepo, Gayatri Sanku, Guillermo Mendez","doi":"10.3332/ecancer.2024.1807","DOIUrl":"10.3332/ecancer.2024.1807","url":null,"abstract":"<p><p>Colorectal cancer is the second leading cause of cancer death in Latin America (LA) with a projected 65.4% increase by 2040. Up to 10% of metastatic CRC (mCRC) patients in LA had an activating BRAF mutation. In clinical trials, targeted therapies for BRAF-V600E mutated mCRC have improved patient outcomes. However, in LA, BRAF-V600E testing and treatment of positive patients remains variable. To address this need, the Americas Health Foundation convened a meeting of LA experts on <i>BRAF-V600E</i> mCRC to develop treatment recommendations. The expert panel addressed the current landscape of BRAF-V600E mCRC testing, diagnosis and treatment in the region and identified significant limitations. Local guidelines, multidisciplinary boards, and tumor genotyping are among the recommendations. The panel also made first-line, second-line and surgery recommendations for patients after diagnosis.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1807"},"PeriodicalIF":1.2,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11959131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and clinicopathological characteristics of de novo metastatic cancer at a major radiotherapy centre in West Africa: a cross-sectional study.","authors":"Joseph Daniels, Onesmus Iinekela Amunyela, Andrew Yaw Nyantakyi, Edwina Ayaaba Ayabilah, Judith Naa Odey Tackie, Kofi Adesi Kyei","doi":"10.3332/ecancer.2024.1805","DOIUrl":"10.3332/ecancer.2024.1805","url":null,"abstract":"<p><strong>Background: </strong>Cancer is a major public health challenge in West Africa, with a significant proportion of cancer-related deaths attributed to distant metastasis. De novo metastatic cancer (DnMC), where metastasis is detected at diagnosis, presents considerable therapeutic challenges, particularly in limited-resource settings where novel treatments are often unavailable and/or unaffordable.</p><p><strong>Aim: </strong>To determine the prevalence, incidence and clinicopathological characteristics of patients diagnosed with DnMC at a major radiotherapy center in West Africa.</p><p><strong>Methods: </strong>This was a single-institution-based quantitative cross-sectional study. Data on the prevalence and incidence of DnMC were retrieved from a hospital-based cancer registry whereas patients' demographic and clinicopathologic data were extracted from patients' medical records and analysed with STATA software (version 16). Descriptive statistics were used to summarise patient- and tumour-related characteristics.</p><p><strong>Results: </strong>The prevalence and incidence of DnMC were 15.2% and 5.3%, respectively, with a 36% overall incidence rate of metastatic cancer. The mean age was 50.9 years (SD 15.2), ranging from 15 to 90 years, with a male-to-female ratio of 1:1.6. Also, 28.8% had a history of alcohol intake whereas 13.7% were (tobacco) smokers. Additionally, 10.3% of the patients had a positive family history of cancer. Pain (28.2%) was the most common presenting symptom, followed by bleeding (16.5%). In all, 34.9% had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 whereas 33.3% were ECOG 1. The gastrointestinal tract (25.8%) and breasts (17.6%) were the most frequent primary cancer sites, whereas 4.4% had metastatic cancers of unknown primary origin. The most frequent sites of distant metastasis were the lungs (34.6%), liver (28.9%) and bone (13.8%). Adenocarcinoma was the most prevalent histological type (35.2%).</p><p><strong>Conclusion: </strong>There was a relatively high rate of DnMC compared with high-income countries, emphasising the need for early detection and expanded access to comprehensive cancer care in limited-resource settings.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1805"},"PeriodicalIF":1.2,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 31-year-old male with a plasmacytoid dendritic blast cell neoplasm.","authors":"Danay Caballero Hernández, Darío Álvaro Rueda, Leticia Rapan, Marcelo Iastrebner, Miguel Sorrentino","doi":"10.3332/ecancer.2024.1806","DOIUrl":"10.3332/ecancer.2024.1806","url":null,"abstract":"<p><p>Plasmacytoid blast dendritic cell neoplasm is a rare subtype of acute leukaemia that represents less than 1% of haematologic neoplasms. It is characterised by skin involvement and leukaemic dissemination in the rest of the body. The immunophenotype is represented by the expression of CD4, CD56 and CD123. Due to its low incidence, there is no standardised treatment. For most authors, acute lymphoblastic leukaemia) regimens with or without consolidation with allogeneic transplantation seem to be the most appropriate. We present the case of a 31-year-old male with a history of von Willebrand's disease, who was diagnosed with plasmacytoid blast dendritic cell neoplasm with central nervous system involvement. After receiving first-line immunopolychemotherapy with rituximab, the patient achieved complete haematologic remission with the high-dose ara-C regimen. Subsequently, he consolidated with allogeneic haploidentical transplantation.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1806"},"PeriodicalIF":1.2,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes following CyberKnife robotic radiosurgery for pituitary adenomas-a large single-centre study.","authors":"Kamran Saeed, Kaynat Siddiqui, Hafiza Fatima Aziz, Fatima Shaukat, Shazia Kadri, Aneeta Ghulam Muhammad, Aneela Darbar, Tariq Mahmood","doi":"10.3332/ecancer.2024.1803","DOIUrl":"10.3332/ecancer.2024.1803","url":null,"abstract":"<p><strong>Introduction: </strong>The role of stereotactic radiosurgery (SRS) in pituitary adenomas (PAs) is evolving especially considering its safety. Existing literature is hampered by limited sample sizes and short-term follow-ups, impeding its preeminence in the clinical and radiological outcomes. We propose a comprehensive, single-centred study to evaluate the outcomes following CyberKnife stereotactic radiosurgery (CK SRS) for PAs in a larger patient population, incorporating meticulous clinical and radiological follow-up.</p><p><strong>Methods: </strong>This is a retrospective cohort study of 278 cases of PAs that underwent CK SRS from 2013 to 2021. Based on their endocrinology profile, they were classified as functional adenomas (FA) and non-functional adenomas (NFA). We assessed pre and post-CK SRS clinical, visual, hormonal and radiological parameters and the associated toxicity. Where applicable, data were compared using the Independent t-test, chi-square test, Fisher Exact and Mann-Whitney <i>U</i> test. A <i>p</i>-value <0.05 was considered significant.</p><p><strong>Results: </strong>The median age of the patients was 40.13 ± 12.61 years (111 female and 167 male patients). The median prescribed radiosurgery dose was 25.0 ± 5.0 Gy into 3 or 5 fractions. The median follow-up time was 12 months (IQR 20). Data were grouped into NFA (169, 60.8%) and FA (109, 39.2%). After adjusting for patients lost to follow-up, post-CK SRS visual perimetry improved in 80.4% of patients and tumour size reduced in 78.6% of the study population. Seventeen patients with NFA and nine with FA manifested new-onset hormonal deficiencies. No statistically significant differences were seen in post-CK SRS visual outcomes and hormone deficiency groups.</p><p><strong>Conclusion: </strong>CK SRS is effective and safe for managing PAs, achieving tumour control and preserving visual function with minimal toxicity. Extended follow-up is needed to evaluate post-SRS toxicity and hypopituitarism.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1803"},"PeriodicalIF":1.2,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling Eribulin's role in metastatic breast cancer: evaluating benefits for both triple negative and non-triple negative patients in real-world scenarios in resource-constrained settings.","authors":"Akhil Kapoor, Anuj Gupta, Bipinesh Sansar, Pooja Gupta, Bal Krishna Mishra, Arpita Singh, Arvind Upadhyay, Amit Kumar, Mayank Tripathi, Zachariah Chowdhury, Shashikant Patne, Ipsita Dhal, Neha Singh, Shreya Shukla, Satyendra Narayan Singh, Lincoln Pujari, Prashanth Giridhar, Ankita Rungta Kapoor, Yash Jain, Manikandan Venkatachalam, Somnath Dey, Kunal Ranjan Vinayak","doi":"10.3332/ecancer.2024.1804","DOIUrl":"10.3332/ecancer.2024.1804","url":null,"abstract":"<p><strong>Background: </strong>Metastatic breast cancer (MBC) patients have numerous options for treatment. However, it is essential to consider treatments with favorable toxicity profiles and convenient modes of administration. Eribulin has shown effectiveness in aggressive MBC, but there is a lack of sufficient real-world data specific to Indian patients.</p><p><strong>Patients and methods: </strong>We conducted a retrospective audit of patients with MBC who received intravenous Eribulin between 2019 and 2023 at a dosage of 1.4 mg/m² on days 1 and 8 every 3 weeks. The median Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>During the specified time, 107 consecutive patients with MBC received Eribulin treatment. The median age was 52 years (range, 28-75 years) with 3 patients with male breast cancer. The median number of prior chemotherapy lines and involved sites were 3 (range, 2-5) and 3 (range, 1-6), respectively. Visceral involvement was present in 84 (78.5%) patients. A median of 3 cycles of Eribulin (range, 1-11) was administered. Eribulin resulted in partial responses in 49 (45.8%) patients, stable disease in 11 (10.3%) patients and progressive disease in 47 (43.9%) patients. The median PFS was 4.0 months (95% CI: 3.4-4.6), and the median OS was 10.0 months (95% CI: 8.3-11.7). For patients with triple-negative breast cancer (TNBC), the median OS was 8 months (95% CI: 5.6-10.4), whereas non-TNBC patients had a median OS of 11 months (95% CI: 9.1-12.8) (hazard ratio, 1.9, 95% CI: 1.2-3.1, <i>p</i> = 0.002). Eribulin was well-tolerated, with dose reduction was needed in 9 (8.4%) of the patients in the overall cohort.</p><p><strong>Conclusion: </strong>Eribulin is a viable and safe option for treating heavily pre-treated MBC in real-world settings. The study found comparable efficacy in both TNBC and non-TNBC patients.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1804"},"PeriodicalIF":1.2,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudovascular squamous cell carcinoma of the buccal mucosa-a rare case report and review of literature.","authors":"Rituparna Dhekial, Rukmini Bezbaruah, Arpan Choudhury, Anupam Das, Sakshi Gupta","doi":"10.3332/ecancer.2024.1802","DOIUrl":"https://doi.org/10.3332/ecancer.2024.1802","url":null,"abstract":"<p><p>Squamous cell carcinoma is the most common malignancy of the head and neck. Pseudovascular squamous cell carcinoma (PSCC) is a rare variant that occurs commonly in the skin of the head and neck. However, oral cavity involvement is extremely rare, with only a few cases reported to date. This variant is associated with an adverse prognosis. Morphologically, the tumour shows marked acantholysis and anastomosing channels mimicking vascular neoplasms. This rare variant poses a diagnostic challenge for pathologists and the accurate diagnosis can be made with the help of immunohistochemical (IHC) studies. A 72-year-old male patient was referred to our hospital with a fast-growing left-sided oral ulcer for more than 1 month. Wide local excision with segmental mandibulectomy was performed and the specimen was sent to our department. On gross examination, a large, soft, lobulated mass was identified in the lower alveolus and the buccal mucosa. On microscopic examination, the tumour was composed of malignant epithelial cells arranged in nests, trabeculae and irregular anastomosing channels. Marked acantholysis and pseudo vascular spaces lined by atypical cells were seen. IHC examination revealed tumour cells positive for CK, P40, P63 and Vimentin and negative for CD31, CD34, S100 and HMB45. The pathological diagnosis was confirmed as PSCC. A short history of the case and a review of literature is discussed here.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1802"},"PeriodicalIF":1.2,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basophils may as a risk factor for upper gastrointestinal cancer: a Mendelian randomization (MR) study.","authors":"Pengkhun Nov, Wandan Li, Duanyu Wang, Socheat Touch, Samnang Kouy, Peizan Ni, Qianzi Kou, Ying Li, Chongyang Zheng, Arzoo Prasai, Wen Fu, Kunpeng Du, Syphanna Sou, Jiqiang Li","doi":"10.3332/ecancer.2024.1799","DOIUrl":"10.3332/ecancer.2024.1799","url":null,"abstract":"<p><strong>Objective: </strong>Upper gastrointestinal (UGI) cancers, including esophageal (EC) and gastric (GC) cancers, pose a significant global health challenge. Previous studies have indicated a fundamental correlation between basophil count and the risk of UGI cancer. However, confirming a causal relationship demands further investigation. Mendelian randomization (MR) provides a critical method for evaluating the possible causal connections between peripheral circulating blood cells (PCBCs) and UGI cancer.</p><p><strong>Method: </strong>Our study comprehensively employed a two-sample MR analysis. We used publicly available genetic data to survey the causal association between PCBC and UGI cancer. We used inverse variance weighting and weighted median for MR analyses and sensitivity analyses to assess heterogeneity and pleiotropy.</p><p><strong>Results: </strong>In terms of the association between PCBCs and UGI cancer, we found that basophils count (EC: OR = 1.416, 95% CI = 1.125-1.783, <i>p</i> = 0.003; GC: OR = 1.623, 95% CI = 1.052-2.505, <i>p</i> = 0.029) were all strongly correlated with both EC and GC. Interestingly, Basophil count was a risk factor for both EC and GC. However, no significant correlations were seen between eosinophil, monocyte, lymphocyte or white blood cell count and UGI cancer.</p><p><strong>Conclusion: </strong>The findings of this research corroborate the idea that basophils might serve as a fundamental risk factor for UGI cancer. Further exploration of the underlying mechanisms driving this relationship could provide crucial understanding helpful in creating prospective preventive and treatment methods for UGI cancer.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1799"},"PeriodicalIF":1.2,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11735140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143001997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}